

# References

## I-9281

1. Casgevy [package insert]. Boston, MA; Vertex, Inc., December 2023. Accessed December 2023.
2. Frangoul H, Altshuler D, Cappellini D, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and  $\beta$ -Thalassemia. Jan 21, 2021 N Engl J Med 2021; 384:252-260 DOI: 10.1056/NEJMoa2031054.
3. Bender MA, Carlberg K. Sickle Cell Disease. 2003 Sep 15 [Updated 2022 Nov 17]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1377/>.
4. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.
5. Tisdale JF, Pierciey FJ, Bonner M, et al. (2020) Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. Am J Hematol E239–E242. <https://doi.org/10.1002/ajh.25867>.
6. Palmer J, McCune JS, Perales M-A, et al. (2016) Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant 1915–1925. <https://doi.org/10.1016/j.bbmt.2016.07.013>
7. Brunson A, Keegan THM, Bang H, et al. (2017) Increased risk of leukemia among sickle cell disease patients in California. Blood 130:1597–1599. doi: 10.1182/blood-2017-05-783233.
8. Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ (2016) Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J R Soc Med 109:303–309. doi: 10.1177/0141076816651037.

9. Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. *Prog Mol Biol Transl Sci.* 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.
10. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. *N Engl J Med.* 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
11. Modarai SR, Kanda S, Bloh K, et al. Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples. *Gene Ther.* 2021 Feb;28(1-2):105-113. doi: 10.1038/s41434-020-00192-z. Epub 2020 Sep 1.
12. Origa R. Beta-Thalassemia. 2000 Sep 28 [Updated 2023 July 20]. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1426/>. Accessed January 2024.
13. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene Autotemcel Gene Therapy for Non- $\beta(0)/\beta(0)$  Genotype  $\beta$ -Thalassemia. *N Engl J Med.* 2022 Feb 3;386(5):415-427. doi: 10.1056/NEJMoa2113206. Epub 2021 Dec 11.